Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

0.4267
+0.00631.50%
Post-market: 0.42670.00000.00%16:04 EDT
Volume:167.26K
Turnover:71.93K
Market Cap:16.11M
PE:-0.98
High:0.4500
Open:0.4500
Low:0.4052
Close:0.4204
52wk High:1.98
52wk Low:0.2500
Shares:37.77M
Float Shares:25.85M
Volume Ratio:1.17
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4366
EPS(LYR):-0.4366
ROE:-2174.98%
ROA:-247.30%
PB:-10.33
PE(LYR):-0.98

Loading ...

Neurosense Achieves Primary Endpoint in Phase 2B ALS Study with Statistically Significant Reduction of Tdp-43, the Defining Pathological Hallmark of ALS

THOMSON REUTERS
·
Jun 29

Neurosense Therapeutics - Primec Shows Favorable Safety Profile with no New Safety Signals over 18 Months

THOMSON REUTERS
·
Jun 29

Neurosense Reports Positive Biomarker Findings from Phase 2 Road Proof-of-concept Study of Primec in Alzheimer's Disease

THOMSON REUTERS
·
Jun 25

NeuroSense joins EverythingALS community event on PrimeC data in ALS

Reuters
·
Jun 22

NeuroSense CEO Alon Ben-Noon acquires 250,000 shares worth USD 200,000

Reuters
·
Jun 18

Neurosense Therapeutics - Granted South Korean Patent Covering Primec Composition for ALS

THOMSON REUTERS
·
Jun 11

NeuroSense wins South Korean patent for PrimeC ALS drug composition through 2042

Reuters
·
Jun 11

Roth MKM Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)

TIPRANKS
·
Jun 10

NeuroSense secures Japan patent for PrimeC ALS drug formulation through 2042

Reuters
·
Jun 09

NeuroSense meets Health Canada on PrimeC regulatory pathway for ALS drug submission

Reuters
·
Jun 08

NeuroSense prices $600,000 private placement at $0.8 per share

Reuters
·
Apr 29

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)

TIPRANKS
·
Apr 27

NeuroSense announces departure of Chief Medical Officer

TIPRANKS
·
Apr 27

NeuroSense CMO Ferenc Tracik steps down, effective April 27

Reuters
·
Apr 24

NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042

Reuters
·
Apr 06

NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement

Reuters
·
Apr 03

Neurosense Therapeutics Ltd. (NRSN) Receives a Buy from Roth MKM

TIPRANKS
·
Apr 02

NeuroSense files Form 3 as CFO Or Eisenberg reports beneficial ownership

Reuters
·
Apr 02

NeuroSense FY25 net loss widens 9% to USD 11.1 million

Reuters
·
Apr 01

NeuroSense Therapeutics director Revital Mandil-Levin files initial beneficial ownership statement

Reuters
·
Apr 01